Humans Female *Urinary Bladder Neoplasms/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Prognosis Proportional Hazards Models Meta-analysis Muscle-invasive bladder urothelial carcinoma Non-muscle-invasive bladder urothelial carcinoma Sex

Humans *Carcinoma Transitional Cell/drug therapy *Urinary Bladder Neoplasms/pathology *Urologic Neoplasms/drug therapy/pathology Antibodies Monoclonal/adverse effects

Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

Humans Cystectomy/adverse effects Prospective Studies Quality of Life *Robotics Treatment Outcome *Robotic Surgical Procedures/adverse effects Postoperative Complications/etiology *Urinary Bladder Neoplasms/pathology

Humans Mitomycin/therapeutic use Antibiotics Antineoplastic BCG Vaccine/therapeutic use *Non-Muscle Invasive Bladder Neoplasms Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Administration Intravesical Neoplasm Invasiveness Bladder cancer Device-assisted Emda Intravesical drug administration Nmibc

Humans *Urinary Bladder/pathology Cystectomy/methods Prognosis Prospective Studies Neoplasm Recurrence Local/pathology *Urinary Bladder Neoplasms/pathology Biomarkers biomarker neutrophil-to-lymphocyte ratio prognostic factor radical cystectomy recurrence urothelial carcinoma

Humans *Carcinoma Transitional Cell *Urinary Bladder Neoplasms/pathology Retrospective Studies BCG Vaccine/therapeutic use Administration Intravesical Adjuvants Immunologic *Organ Transplantation Neoplasm Invasiveness Neoplasm Recurrence Local/pathology Bcg Bladder cancer Chemotherapy Mitomycin Transplanted patients

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Area Under Curve *Carcinoma Transitional Cell Humans In Situ Hybridization Fluorescence ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/pathology Biomarker Cytology Diagnostic Fluorescent in situ hybridization (FISH) Meta-analysis Upper urinary tract urothelial carcinoma (UTUC)

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

Cystectomy/adverse effects Female Humans Male Network Meta-Analysis *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures Tueb Turbt bladder cancer en bloc transurethral en bloc transurethral resection

*Cystectomy Humans Prospective Studies Systematic Reviews as Topic Treatment Outcome Urinary Bladder/pathology/surgery *Urinary Bladder Neoplasms/pathology/surgery models mortality nomograms radical cystectomy urinary bladder neoplasms

Apoptosis B7-H1 Antigen/genetics/metabolism *Carcinoma Transitional Cell/pathology Cystectomy Humans Immune Checkpoint Inhibitors Ligands Lymph Node Excision Neoplasm Recurrence Local/pathology Prognosis Programmed Cell Death 1 Receptor Urinary Bladder *Urinary Bladder Neoplasms/pathology bladder urothelial carcinoma meta-analysis prognostic value programmed cell death ligand-1 radical cystectomy commercial or financial relationships that could be construed as a potential conflict of interest.

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

Autoantigens Biomarkers Tumor/genetics/metabolism Gene Expression Regulation Neoplastic Humans Procollagen-Lysine 2-Oxoglutarate 5-Dioxygenase/genetics/metabolism Prognosis *Urinary Bladder Neoplasms/pathology Bladder cancer Meta-analysis Microarray datasets Overall survival Prognostic biomarker

Humans *Urinary Bladder Neoplasms/pathology Consensus Urothelium/pathology *Urologic Neoplasms/pathology Flat lesion Gups Papillary lesion Urothelial neoplasia

Humans *Carcinoma Transitional Cell/secondary *Urinary Bladder Neoplasms/pathology

Humans Biomarkers Tumor *Carcinoma in Situ/diagnosis *Carcinoma Transitional Cell/pathology Hyaluronan Receptors/metabolism Keratin-20/analysis/metabolism Ki-67 Antigen/metabolism Tumor Suppressor Protein p53/analysis/metabolism Urinary Bladder *Urinary Bladder Neoplasms/pathology Urothelium/chemistry/metabolism/pathology Bladder carcinoma Carcinoma in situ Carcinoma vesical Displasia Dysplasia Immunomarkes Inmunomarcadores

Humans *Laser Therapy/adverse effects Outpatients *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures *Ablation *Bladder cancer *Fulguration *Laser *Non–muscle-invasive bladder cancer *Outpatient